ZTS

Zoetis Inc. (ZTS) Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Zoetis Inc. is a global leader in the animal health industry, operating in two geographic segments: the United States and International. The company markets products for companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish, sheep). Notably, the company completed the divestiture of its medicated feed additive portfolio in October 2024, which impacts year-over-year comparisons.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Q3 revenue increased 1% ($12M) year-over-year. Operational revenue was flat, driven by ~4% price growth and ~1% volume growth from in-line products, offset by a ~4% volume decrease due to the medicated feed additive divestiture and a ~1% volume decrease in key franchises. Foreign exchange contributed a 1% positive impact.
• Profitability: Net income increased 6% in Q3 and 9% for the nine-month period. The effective tax rate for Q3 was 18.7%, lower than the prior year's 20.8%, primarily due to higher net discrete tax benefits.
• Segment Performance:
  • U.S. Segment: Revenue decreased 2% in Q3 due to a decline in livestock products (impact of divestiture), partially offset by growth in companion animal products (parasiticides, dermatology).
  • International Segment: Revenue increased 3% in Q3, driven by a 1% operational increase (companion animal growth) and a 2% favorable foreign exchange impact.
• Debt Refinancing: In August 2025, the company issued $1.85B in new senior notes (4.150% due 2028 and 5.000% due 2035) to redeem $1.35B of maturing debt, extending the debt maturity profile.

Guidance, Outlook, and Risks

• Capital Allocation: The company continues its share repurchase program. As of September 30, 2025, $4.5 billion remains available under the $6 billion authorization. During the first nine months of 2025, 7.3 million shares were repurchased for $1.158 billion.
• Dividends: Dividends declared for the nine months ended September 30, 2025, totaled $1.000 per share.
• Management Commentary: Management highlights strong operational results despite the divestiture impact. Price growth of approximately 4% was a key driver. The company is transitioning from internal to external innovation/manufacturing for certain products, incurring restructuring charges.
• Risks and Contingencies:
  • Tariffs and Trade: New tariffs announced in early 2025 and reciprocal actions by other nations create uncertainty regarding product costs and demand.
  • Tax Audit: The company is under audit by the IRS for tax years 2017 and 2018. The IRS has proposed an additional tax liability of approximately $450 million; Zoetis disagrees with the position and is defending it.
  • Executive Departure: Dr. Robert J. Polzer, Executive Vice President and President of R&D, announced his retirement effective December 31, 2025, with Dr. Kevin Esch succeeding him on January 1, 2026.

Investor Verification Checklist

• Divestiture Impact: Verify the long-term revenue trajectory of the remaining portfolio following the October 2024 medicated feed additive divestiture.
• Tax Liability: Monitor the status of the IRS audit regarding the 2017-2018 tax years and the potential $450 million proposed adjustment.
• Debt Structure: Review the terms of the new 2025 senior notes issued in August and the impact on future interest expense.
• Operational Efficiency: Assess the progress and cost implications of the transition from internal to external manufacturing for specific product lines.
• Share Repurchases: Track the utilization of the remaining $4.5 billion repurchase authorization and its impact on diluted share count.